

Technology appraisal (TA)	Date of TA Release	Adherence of local formulary to NICE	
		Included on the Trust Formulary for this indication Yes OR No	Reason provided if "No"
2023-24			
TA879 - Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment (terminated appraisal)	06/04/2023	No	Terminated appraisal
TA880 - Tezepelumab for treating severe asthma	20/04/2023	No	Not a NICE commissioned site
TA881 - Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatments	03/05/2023	No	Not recommended by NICE
TA882 - Voclosporin with mycophenolate mofetil for treating lupus nephritis	03/05/2023	No	Not a NICE commissioned site
TA883 - Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma	03/05/2023	No	Not recommended by NICE
TA884 - Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping (terminated appraisal)	03/05/2023	No	Terminated appraisal
TA885 - Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer	03/05/2023	No	Condition not treated at CWFT
TA886 - Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy	10/05/2023	Yes	
TA887 - Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer	10/05/2023	Yes	
TA888 - Risankizumab for previously treated moderately to severely active Crohn's disease	17/05/2023	Yes	
TA889 - Ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma (terminated appraisal)	17/05/2023	No	Terminated appraisal
TA890 - Difelikefalin for treating pruritus in people having haemodialysis	17/05/2023	No	Condition not treated at CWFT
TA891 - Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia	31/05/2023	Yes	
TA892 - Mosunetuzumab for treating relapsed or refractory follicular lymphoma	31/05/2023	No	Not recommended by NICE
TA893 - Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over	07/06/2023	No	Condition not treated at CWFT
TA894 - Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphoma	07/06/2023	No	Not recommended by NICE
TA895 - Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy	07/06/2023	No	Condition not treated at CWFT
TA896 - Bulevirtide for treating chronic hepatitis D	07/06/2023	No	Not a NICE commissioned site
TA897 - Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma	06/06/2023	Yes	
TA898 - Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer	14/06/2023	Yes	

TA899 - Esketamine for treating major depressive disorder in adults at imminent risk of suicide (terminated appraisal)	06/06/2023	No	Terminated appraisal
TA900 - Tixagevimab plus cilgavimab for preventing COVID-19	14/06/2023	No	Not recommended by NICE
TA901 - Cemiplimab for treating recurrent or metastatic cervical cancer	20/06/2023	No	Terminated appraisal
TA902 - Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction	21/06/2023	Yes	
TA903 - Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer	21/06/2023	Yes	
TA904 - Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer	21/06/2023	No	Condition not treated at CWFT
TA905 - Upadacitinib for previously treated moderately to severely active Crohn's disease	21/06/2023	Yes	
TA906 - Rimegepant for preventing migraine	05/07/2023	Yes	
TA907 - Deucravacitinib for treating moderate to severe plaque psoriasis	28/06/2023	Yes	
TA908 - Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy	05/07/2023	No	Condition not treated at CWFT
TA909 - Lortatinib for untreated ALK-positive advanced non-small-cell lung cancer	12/07/2023	No	Not recommended by NICE
TA910 - Semaglutide for managing overweight and obesity in young people aged 12 to 17 years (terminated appraisal)	13/07/2023	No	Terminated appraisal
TA911 - Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer	26/07/2023	Yes	
TA912 - Ciplaglusidase alfa with miglustat for treating late-onset Pompe disease	15/08/2023	No	Not a NICE commissioned site
TA913 - Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy	06/09/2023	No	Not a NICE commissioned site
TA914 - Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency	20/09/2023	Yes	
TA915 - Pegunigalsidase alfa for treating Fabry disease	04/10/2023	No	Not a NICE commissioned site
TA916 - Bimekizumab for treating active psoriatic arthritis	04/10/2023	Yes	
TA917 - Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable	25/10/2023	Yes	

TA918 - Bimekizumab for treating axial spondyloarthritis	11/10/2023	Yes	
TA919 - Rimegepant for treating migraine	18/10/2023	Yes	
TA920 - Tofacitinib for treating active ankylosing spondylitis	18/10/2023	Yes	
TA921 - Ruxolitinib for treating polycythaemia vera	18/10/2023	Yes	
TA922 - Daridorexant for treating long-term insomnia	18/10/2023	Yes	
TA923 - Tabelecleucel for treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus (terminated appraisal)	19/10/2023	No	Terminated appraisal
TA924 - Tirzepatide for treating type 2 diabetes	25/10/2023	Yes	
TA925 - Mirikizumab for treating moderately to severely active ulcerative colitis	25/10/2023	Yes	
TA926 - Baricitinib for treating severe alopecia areata	25/10/2023	No	Not recommended by NICE
TA927 - Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments	17/10/2023	Yes	
TA928 - Cabozantinib for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine	01/11/2023	No	Not recommended by NICE
TA929 - Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction	01/11/2023	Yes	
TA930 - Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments	15/11/2023	No	Not recommended by NICE
TA931 - Zanubrutinib for treating chronic lymphocytic leukaemia	22/11/2023	Yes	
TA932 - Decitabine-cedazuridine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (terminated appraisal)	23/11/2023	No	Terminated appraisal
TA933 - Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (terminated appraisal)	29/11/2023	No	Terminated appraisal
TA934 - Foslevodopa-foscarbidopa for treating advanced Parkinson's with motor symptoms	29/11/2023	No	Condition not treated at CWFT
TA935 - Secukinumab for treating moderate to severe hidradenitis suppurativa	06/12/2023	Yes	
TA936 - Idecabtagene vicleucel for treating relapsed and refractory multiple myeloma after 3 or more treatments (terminated appraisal)	30/11/2023	No	Terminated appraisal

TA937 - Targeted-release budesonide for treating primary IgA nephropathy	20/12/2023	No	Condition not treated at CWFT
TA938 - Dupilumab for treating eosinophilic oesophagitis in people 12 years and over (terminated appraisal)	07/12/2023	No	Terminated appraisal
TA939 - Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer	13/12/2023	No	Condition not treated at CWFT
TA940 - Ravulizumab for treating generalised myasthenia gravis (terminated appraisal)	20/12/2023	No	Terminated appraisal
TA941 - Ravulizumab for treating AQP4 antibody-positive neuromyelitis optica spectrum disorder (terminated appraisal)	20/12/2023	No	Terminated appraisal
TA942 - Empagliflozin for treating chronic kidney disease	20/12/2023	Yes	
TA943 - Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes	19/12/2023	N/A	Medical device
TA944 - Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer	10/01/2024	No	Condition not treated at CWFT
TA945 - Treosulfan with fludarabine before allogeneic stem cell transplant for people aged 1 month to 17 years with non-malignant diseases (terminated appraisal)	30/01/2024	No	Terminated appraisal
TA946 - Olaparib with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer	17/01/2024	No	Condition not treated at CWFT
TA947 - Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments	31/01/2024	Yes	
TA948 - Ivosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatments	31/01/2024	No	Condition not treated at CWFT
TA949 - Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and over	07/02/2024	No	Not a NICE commissioned site
TA950 - Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over	07/02/2024	Yes	
TA951 - Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer	07/02/2024	Yes	
TA952 - Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations	21/02/2024	Yes	
TA953 - Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema	13/03/2024	Yes	
TA954 - Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments	06/03/2024	Yes	
TA955 - Dupilumab for treating moderate to severe prurigo nodularis	13/03/2024	No	Not recommended by NICE

TA956 - Etrasimod for treating moderately to severely active ulcerative colitis in people aged 16 and over	11/03/2024	Yes	
TA957 - Mometinib for treating myelofibrosis-related splenomegaly or symptoms	20/03/2024	Yes	
TA958 - Ritlecitinib for treating severe alopecia areata in people 12 years and over	27/03/2024	Yes	
TA959 - Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis	27/03/2024	Yes	
TA960 - Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders (terminated appraisal)	27/03/2024	No	Terminated appraisal
TA961 - Sebelipase alfa for treating lysosomal acid lipase deficiency that is not Wolman disease (terminated appraisal)	28/03/2024	No	Terminated appraisal
TA962 - Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy	28/03/2024	No	Condition not treated at CWFT